Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.40 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097046 | 0.78 | LRRK2 (0.44) | CLK2LRRK2AURKAAURKBINCENP | |
| SCHEMBL30274556 | 0.78 | LRRK2 (0.44) | CLK2LRRK2AURKAAURKBINCENP | |
| SCHEMBL17820257 | 0.77 | ERN1 (0.46) | LRRK2AURKAAURKBINCENPTPX2 | |
| SCHEMBL23753887 | 0.76 | MTOR (0.43) | CLK2LRRK2AURKAAURKBINCENP | |
| SCHEMBL29447089 | 0.76 | CLK2 (0.46) | CLK2LRRK2AURKAAURKBINCENP | |
| SCHEMBL29961343 | 0.75 | CLK2 (0.56) | CLK2LRRK2AURKBCHEK1MKNK1 | |
| SCHEMBL29961620 | 0.75 | CLK2 (0.56) | CLK2LRRK2CHEK1MKNK1IRAK4 | |
| SCHEMBL4585500 | 0.74 | CCR1 (0.46) | ALDH1A1MPIKMT2A | |
| SCHEMBL24920777 | 0.74 | ACVR2A (0.46) | CLK2LRRK2AURKAAURKBINCENP | |
| SCHEMBL13086431 | 0.74 | IRAK1 (0.41) | CLK2LRRK2AURKAAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577229-B2 | Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors | ELI LILLY AND COMPANY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4146641-B1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | LILLY CO ELI (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-115768520-B | Substituted { 5-methoxy-6- [ (5-methoxypyridin-2-yl) methoxy ] pyridin-3-yl } methyl compounds as CSF-1R inhibitors | 伊莱利利公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20230167086-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167086-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167086-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| CN-115768520-A | Substituted { 5-methoxy-6- [ (5-methoxypyridin-2-yl) methoxy ] pyridin-3-yl } methyl compounds as CSF-1R inhibitors | 伊莱利利公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2021225798-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | ELI LILLY AND COMPANY (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577229-B2 | Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors | CSF1R, CSF3R, AGER | CLK2 2026/4885LRRK2 392/4885ALDH1A1 1048/4885 |
| US-20230167086-A1 | SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS | CSF1R, CSF3R, IL1RN | CLK2 2480/4885LRRK2 637/4885ALDH1A1 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.